Facebook Pixel

FDA Halts 2 Firms From Marketing Unapproved Cold Medications

Rate This

The U.S. Food and Drug Administration secured a court order barring a New Jersey pharmaceutical company from distributing more than 50 unapproved cough and cold medicines, the Associated Press reported Friday.

East Windsor, N.J.-based Advent Pharmaceuticals continued to market the unapproved products despite prior warnings, and failed to correct manufacturing problems identified by FDA inspectors, the AP said. Advent products and those from its subsidiary, Neilgen Pharmaceuticals, covered in the order include BP Allergy Junior Suspension, RE All 12 Suspension, and many others, the AP reported. Neilgen, based in Westminster, Md., also does business as Unigen Pharmaceuticals, the FDA said.

Consumers were urged to discontinue use of the products and to consult with a physician for alternatives. Company officials did not immediately respond to calls for comment Friday afternoon, the AP said.

A complete list of the unapproved cold medications is available on the FDA Web site at www.fda.gov/bbs/topics/NEWS/2009/NEW01995.html.

Add a Comment1 Comments

EmpowHER Guest

FDA Gets Permanent Injunction Against Neilgen, Advent Pharmaceuticals for Selling Defective Drugs: http://www.newsinferno.com/archives/5587#more-5587

April 13, 2009 - 2:29pm
Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy
Add a Comment

Lung Conditions

Get Email Updates

Lung Conditions Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!